0.4135 0.034 (8.96%) | 02-05 15:58 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 0.44 | 1-year : | 0.61 |
Resists | First : | 0.38 | Second : | 0.52 |
Pivot price | 0.16 ![]() |
|||
Supports | First : | 0.14 | Second : | 0.12 |
MAs | MA(5) : | 0.16 ![]() |
MA(20) : | 0.16 ![]() |
MA(100) : | 0.32 ![]() |
MA(250) : | 0.5 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 43.3 ![]() |
D(3) : | 50.7 ![]() |
RSI | RSI(14): 35.3 ![]() |
|||
52-week | High : | 0.88 | Low : | 0.14 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NHWK ] has closed below upper band by 48.3%. Bollinger Bands are 87.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 0.17 - 0.17 | 0.17 - 0.17 |
Low: | 0.16 - 0.16 | 0.16 - 0.16 |
Close: | 0.16 - 0.16 | 0.16 - 0.17 |
NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. The company has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is headquartered in Morrisville, North Carolina.
Wed, 07 Feb 2024
NightHawk Biosciences Debuts SCPX Ticker on NYSE American - TipRanks
Mon, 08 Jan 2024
NightHawk Biosciences Announces Planned Name Change to - GlobeNewswire
Mon, 18 Dec 2023
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Markets Insider
Wed, 13 Dec 2023
NightHawk CEO to acquire subsidiary as company turns to manufacturing - The Business Journals
Thu, 24 Aug 2023
Morrisville CEO pitches to buy his company's subsidiary for $45M+ - The Business Journals
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
AMEX
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | -26 (M) |
Shares Float | 0 (M) |
Held by Insiders | 2.608e+007 (%) |
Held by Institutions | 2.474e+007 (%) |
Shares Short | 0 (K) |
Shares Short P.Month | 0 (K) |
EPS | 0 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -2.05 |
Profit Margin | 0 % |
Operating Margin | -1 % |
Return on Assets (ttm) | 529.4 % |
Return on Equity (ttm) | -36.1 % |
Qtrly Rev. Growth | 8.24e+006 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -4.764e+007 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | 0 |
PEG Ratio | 0 |
Price to Book value | -0.09 |
Price to Sales | 0 |
Price to Cash Flow | 0 |
Dividend | 303690 |
Forward Dividend | 292440 |
Dividend Yield | 184614000% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |